Search filters
Filters
Clear All

Phase

  • 13
  • 1
  • 10
  • 6
  • 175
  • 206
  • 166
  • 1
  • 5
  • 200

Found 206 cc-cancer-center trials

A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

S2114 A randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma

99 years and younger
All genders
To compare the progression-free survival in participants with relapsed/refractory large B-cell lymphoma or follicular lymphoma grade 3B with stable disease (SD) or partial remission (PR) on first imaging response by central review (day +30PET/CT scan) after commercial CD19 CAR T-cell therapy
Learn More

13523: Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma

99 years and younger
All genders
This research study is designed to learn more about the safety and effectiveness of lurbinectedin given to individuals who have been diagnosed with metastatic leiomyosarcoma. Participants are being invited to participate in this research study because they have metastatic leiomyosarcoma.
Learn More

A051902: A randomized phase II study of CHO(E)P vs CC-486- CHO(E)P vs duvelisib- CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas

99 years and younger
All genders
This study evaluates the effects (good or bad) of adding a study drug (duvelisib or CC-486 (azacitidine)) to the usual combination of drugs. Eligible participants will be those with stage I-IV CD30 negative peripheral T-cell lymphoma that has not been previously treated.
Learn More

UPCC 50923 A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors

99 years and younger
All genders
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161. We would like to rely on WCG IRB as the IRB of record for this study.
Learn More

UPCC 19523: A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

99 years and younger
All genders
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. We would like to rely on Advarra as the IRB …
Learn More

UPCC 19922 Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

99 years and younger
All genders
This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur.
Learn More

UPCC 33423 A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD30-Positive Peripheral T-Cell Lymphoma (Lumin

99 years and younger
All genders
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
Learn More

A031501: Phase III randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADvanced urOthelial caRcinoma (AMBASSADOR) versus observation

99 years and younger
All genders
We would like to rely on the NCI CIRB as IRB of record for this study. The purpose of this study is to compare any good and bad effects of using a drug called MK-3475 (pembrolizumab) after the removal of muscle invasive bladder cancer.
Learn More

EA7211: A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)

99 years and younger
All genders
The primary objective of this study is to assess whether preoperative hemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of patients with high risk de-differentiated liposarcoma DDLPS) and leiomyosarcoma (LMS) as measured by disease-free survival.
Learn More

UPCC 20522 A Phase 1 Open-Label Study of Patritumab Deruxtecan in Combination with Osimertinib in Subjects with Locally Advanced or metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

99 years and younger
All genders
This study includes a Dose Escalation Part to identify the recommended combination dose (RCD) and a Dose Expansion Part to further evaluate efficacy and safety.
Learn More
91 - 100 of 206